American Shared Hospital Services Reports Third Quarter and Nine-Month 2026 Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
American Shared Hospital Services (NYSE American: AMS) reported third-quarter 2026 revenue of $7.6 million, with growth led by Direct Patient Services.
Revenue increased 6.3% year over year, but the attributable net loss widened to $620,000, or $0.09 per diluted share, from $17,000, or $0.00 per diluted share. Direct Patient Services revenue rose 13.6%, while Medical Equipment Leasing revenue fell 3.1%.
Nine-month revenue increased 13.7% to $23.1 million; the attributable net loss widened to $1.746 million from $922,000. Operating cash flow reached $5.8 million, versus $3.8 million a year earlier. Cash, cash equivalents and restricted cash totaled $9.485 million at September 30, against $15.7 million in current long-term debt, net. AMS secured $2.0 million in subordinated financing during the third quarter and expects treatments at its San Javier joint venture to begin in mid-2027.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointSubordinated financing from chairman-controlled RCS/TIG Holdings provided $2.0 million in additional funding. 25% of market cap
- Moderate pointNine-month revenue increased 13.7% to $23.1 million from $20.4 million in 2025.
- Moderate pointNine-month operating cash flow increased to $5.8 million from $3.8 million in 2025.
- Moderate pointCash, cash equivalents and restricted cash increased to $9.485 million from $3.712 million at December 31, 2025.
- Moderate pointCurrent long-term debt, net, declined to $15.7 million from $17.3 million at December 31, 2025.
13 minor points
- Minor pointThird-quarter revenue increased 6.3% to $7.6 million from $7.2 million in 2025.
- Minor pointThird-quarter Direct Patient Services revenue increased 13.6% to $4.6 million, versus $4.0 million in 2025.
- Minor pointThird-quarter Rhode Island and Puebla revenue increased 13.5% to $3.3 million, versus $2.9 million in 2025.
- Minor pointInternational Gamma Knife procedure volume increased 8.9% year over year in the third quarter.
- Minor pointDomestic Gamma Knife procedure volume increased 13.1% year over year in the third quarter.
- Minor pointNine-month Direct Patient Services revenue increased 27.0% to $13.5 million from $10.7 million in 2025.
- Minor pointNine-month Rhode Island and Puebla revenue increased to approximately $9.6 million from $7.8 million in 2025.
- Minor pointInternational Gamma Knife procedure volume increased 30.7% in the first nine months versus 2025.
- Minor pointNine-month proton therapy revenue increased to $6.3 million from $5.7 million, reflecting higher average reimbursement.
- Minor pointNine-month proton therapy treatment fractions increased to 3,184 from 3,095 in 2025.
- Minor pointNine-month gross profit increased to $4.240 million from $4.158 million in 2025.
- Minor pointNine-month interest expense declined to $1.083 million from $1.253 million in 2025.
- Minor point. Forward-looking: it has not happened yet and may not happen.San Javier joint venture expansion includes an expected equipment upgrade; AMS expects treatments to begin mid-2027.
Negative
- Major pointSubordinated financing added $2.0 million in debt from an entity controlled by the executive chairman. 25% of market cap
- Moderate pointNine-month attributable net loss widened to $1.746 million, or $0.26 per diluted share, versus $922,000, or $0.14, in 2025.
- Moderate pointNine-month adjusted EBITDA declined to $3.8 million from $4.6 million in 2025.
- Moderate pointNine-month costs of revenue increased to $18.898 million from $16.196 million in 2025, including credit loss reserves.
- Moderate pointNine-month selling and administrative expenses increased to $5.755 million from $5.092 million in 2025.
- Moderate pointNine-month operating loss widened to $2.598 million from $2.187 million in 2025.
- Moderate pointCurrent liabilities of $23.627 million exceeded current assets of $19.059 million at September 30, 2026.
19 minor points
- Minor pointThird-quarter attributable net loss widened to $620,000, or $0.09 per diluted share, versus $17,000, or $0.00, in 2025.
- Minor pointThird-quarter adjusted EBITDA declined to $1.4 million from $1.9 million in 2025.
- Minor pointThird-quarter Medical Equipment Leasing revenue declined 3.1% to $3.0 million from $3.1 million in 2025.
- Minor pointNine-month Medical Equipment Leasing revenue declined approximately 1.0% to $9.6 million from $9.7 million in 2025.
- Minor pointThird-quarter proton therapy revenue declined to $2.0 million from $2.1 million in 2025.
- Minor pointThird-quarter proton therapy treatment fractions declined to 960 from 1,150 in 2025.
- Minor pointRhode Island and Puebla procedures declined to 7,143 in the third quarter from 7,355 in 2025.
- Minor pointRhode Island and Puebla procedures declined to 19,788 over nine months from 20,401 in 2025.
- Minor pointNine-month domestic Gamma Knife volume declined, primarily following one customer contract's April 2025 expiration.
- Minor pointThird-quarter gross profit declined to $1.519 million from $1.586 million in 2025.
- Minor pointThird-quarter costs of revenue increased to $6.105 million from $5.585 million in 2025.
- Minor pointThird-quarter selling and administrative expenses increased to $1.803 million from $1.538 million in 2025.
- Minor pointThird-quarter interest expense increased to $480,000 from $392,000 in 2025.
- Minor pointThird-quarter operating loss widened to $764,000 from $344,000 in 2025.
- Minor pointThird-quarter income tax expense increased to $163,000 from $48,000 in 2025.
- Minor pointNine-month income taxes shifted to $390,000 expense from a $296,000 benefit in 2025.
- Minor pointThird-quarter interest and other income declined to $21,000 from $63,000 in 2025.
- Minor pointNine-month interest and other income declined to $122,000 from $172,000 in 2025.
- Minor pointShareholders' equity declined to $22.608 million from $24.034 million at December 31, 2025.
Details
Market move: AMS -7.63% in the Nov 12 session. 3Q26 earnings report
On Nov 12, the day this news came out, AMS closed 7.63% below the previous close. Argus tracked a trough of -7.5% from its starting point during tracking. Our momentum scanner recorded 7 alerts for this stock that day. That session’s volume was 8.4x the stock’s average daily volume.
Data tracked by StockTitan Argus for the Nov 12 session.
Key Figures
- Third-quarter revenue
- $7.6M (+6.3% year over year)
- Three months ended September 30, 2026
- Nine-month revenue
- $23.1M (+13.7% year over year)
- Nine months ended September 30, 2026
- Direct Patient Services revenue
- $13.5M (+27.0% year over year)
- Nine months ended September 30, 2026
- Third-quarter net loss attributable to AMS
- $620,000 ($0.09 per diluted share)
- Compared with $17,000 ($0.00 per diluted share) in the prior-year quarter
- Nine-month net loss attributable to AMS
- $1.746M ($0.26 per diluted share)
- Compared with $922,000 ($0.14 per diluted share) in the prior-year period
- Nine-month adjusted EBITDA
- $3.828M
- Compared with $4.593M in the prior-year period
- Cash from operating activities
- $5.8M
- First nine months of 2026; compared with $3.8M in the same period of 2025
- Cash, cash equivalents and restricted cash
- $9.485M
- At September 30, 2026; compared with $3.712M at December 31, 2025
Previous Earnings Reports
-
Third-quarter revenue and Direct Patient Services revenue increased year over year.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
adjusted EBITDA financial
forbearance agreement financial
subordinated financing financial
treatment fractions medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Third Quarter Revenue Increased
Nine-Month Revenue Increased
Generated
Cash, Cash Equivalents and Restricted Cash Increased to approximately
Conference Call Scheduled for Today at 12:00 PM ET
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services, today announced financial results for the third quarter and nine months ended September 30, 2026.
Craig Tagawa, Interim Chief Executive Officer, commented, “During the third quarter, we continued to make progress in growing our Direct Patient Services business, with revenue in this segment increasing
Ray Stachowiak, Executive Chairman, stated, “We continue to focus on positioning the Company for long-term success by building on our established presence in radiation oncology and pursuing opportunities to expand the reach and capabilities of our technology and services. We believe our combination of specialized treatment capabilities, experienced operating teams, and relationships with leading healthcare institutions provides a foundation from which to create additional value. Additionally, our joint venture initiative with Hospital San Javier in Guadalajara, Mexico, represents an important opportunity to extend our Gamma Knife presence into another market. Our broader priority remains focused on the disciplined management of our assets, strengthening our financial foundation, and pursuing strategic opportunities that can contribute to sustainable long-term growth and shareholder value.”
Third Quarter 2026 Results
Total revenue for the third quarter of 2026 increased
Direct Patient Services segment revenue increased
Within the Company's international Gamma Knife operations in Peru and Ecuador, procedure volume increased
Medical Equipment Leasing segment revenue was
Gross profit for the third quarter was
Selling and administrative expenses increased to
The Company reported a net loss attributable to American Shared Hospital Services of
Third quarter adjusted EBITDA was
Nine-Month 2026 Results
For the first nine months of 2026, total revenue increased
Direct Patient Services segment revenue increased
At the Company's international Gamma Knife facilities in Peru and Ecuador, procedure volume increased
Medical Equipment Leasing segment revenue was
Gross profit for the first nine months of 2026 was consistent with the prior-year period of
Selling, general and administrative expenses increased to
The Company reported a net loss attributable to American Shared Hospital Services of
Adjusted EBITDA for the nine-month period was
Balance Sheet Highlights
At September 30, 2026, the Company had cash, cash equivalents and restricted cash of approximately
For the first nine months of 2026, the Company generated
The current portion of long-term debt, net was
Shareholders’ equity attributable to American Shared Hospital Services, excluding non-controlling interests, was
As previously disclosed during the third quarter, the Company entered into a Third Amendment to its Credit Agreement and Forbearance Agreement with Fifth Third Bank. In conjunction with the amendment, the Company secured
Management believes the third quarter financing and the agreement reached with Fifth Third Bank actions provide additional flexibility while the Company continues exploring longer-term capital structure alternatives designed to support future growth initiatives and strengthen its balance sheet.
San Javier Joint Venture
The Company is continuing to advance its joint venture with Hospital San Javier, S.A. de C.V. in Guadalajara, Mexico. AMS expects to upgrade the hospital's existing Gamma Knife Perfexion system to a Gamma Knife Esprit system and expects patient treatments at the facility to begin in mid-2027. The San Javier initiative represents a potential opportunity to extend AMS's Gamma Knife presence into another market and expand its international Direct Patient Services platform.
Strategic Growth Initiatives
"Our strategy remains focused on building a differentiated platform of advanced radiation therapy technologies and services that address the growing demand for precision cancer treatment," said Ray Stachowiak, Executive Chairman. "Our combination of Gamma Knife, Proton Beam Radiation Therapy and direct patient services provide the Company with multiple opportunities to expand our geographic reach, increase treatment volumes and drive long-term growth. We believe our diversified platform and established healthcare partnerships provide a strong foundation for capitalizing on these opportunities.”
"As we continue to evaluate our capital structure strategies, our underlying operating business is demonstrating encouraging progress. During the first nine months of 2026, we achieved
"Our priorities remain focused on improving operational performance, increasing utilization across our existing network, expanding access to advanced radiation therapy services and strengthening our financial position. We remain committed to disciplined capital allocation and believe that continued execution of these initiatives positions the Company for sustainable long-term shareholder value."
Conference Call
The Company will hold a conference call to discuss its third quarter financial results today at 12:00 pm ET.
Teleconference and Webcast Information
To participate, domestic callers may dial 1-844-413-3972 and international callers may dial 1-412-317-5776 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
A simultaneous webcast of the call may be accessed through the Company's website, www.ashs.com or directly:
https://event.choruscall.com/mediaframe/webcast.html?webcastid=nqCysq92
A replay of the call will be available at 1-855-669-9658 or 1-412-317-0088, access code 6458694, through November 19, 2026. The call will also be available for replay on the Company’s website at www.ashs.com.
About American Shared Hospital Services (NYSE American: AMS)
American Shared Hospital Services (AMS) is a leading provider of turnkey solutions to cancer treatment centers, health systems, and cancer networks in North and South America. The Company works closely with its partners to develop and grow their cancer service lines and provide integrated cancer care to patients in a convenient local setting close to home. For centers under health system partnerships, the Company and its health system partners share in the capital investment cost and profitability of the operations based on their respective ownership interests. For more information, please visit: www.ashs.com
Safe Harbor Statement
This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton beam radiation therapy and direct patient care services business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risk of compliance with debt covenants, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton beam radiation therapy and direct patient care services businesses, the risks of changes to Centers for Medicare & Medicaid Services reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, PBRT, and direct patient care services businesses, the risk of expanding within or into new markets, the risk that the continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent reports filed by the Company with the Securities and Exchange Commission.
Non-GAAP Financial Measure
Adjusted EBITDA, the non-GAAP measure presented in this press release and supplementary information, is not a measure of performance under the accounting principles generally accepted in the United States ("GAAP"). This non-GAAP financial measure has limitations as an analytical tool, including that it does not have a standardized meaning. When assessing our operating performance, this non-GAAP financial measure should not be considered a substitute for, and investors should also consider, income before income taxes, income from operations, net income attributable to the Company, earnings per share and other measures of performance as defined by GAAP as indicators of the Company's performance or profitability.
EBITDA is a non-GAAP financial measure representing our earnings before interest expense, interest income, income tax expense (benefit), depreciation, and amortization. We define Adjusted EBITDA as net loss before interest expense, interest income, income tax expense (benefit), depreciation and amortization expense, and stock-based compensation expense.
We use this non-GAAP financial measure as a means to evaluate period-to-period comparisons. Our management believes that this non-GAAP financial measure provides meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as stock-based compensation expense. We believe that both management and investors benefit from referring to this non-GAAP financial measure in assessing our performance.
Contacts
American Shared Hospital Services
Ray Stachowiak, Executive Chairman
rstachowiak@ashs.com
Investor Relations
Kirin Smith, President
PCG Advisory, Inc.
ksmith@pcgadvisory.com
| American Shared Hospital Services | ||||||||||||||||
| Condensed Consolidated Statements of Operations | ||||||||||||||||
| Summary of Operations Data | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | $ | 7,624,000 | $ | 7,171,000 | $ | 23,138,000 | $ | 20,354,000 | ||||||||
| Costs of revenue | 6,105,000 | 5,585,000 | 18,898,000 | 16,196,000 | ||||||||||||
| Gross margin | 1,519,000 | 1,586,000 | 4,240,000 | 4,158,000 | ||||||||||||
| Selling and administrative expense | 1,803,000 | 1,538,000 | 5,755,000 | 5,092,000 | ||||||||||||
| Interest expense | 480,000 | 392,000 | 1,083,000 | 1,253,000 | ||||||||||||
| Operating loss | (764,000 | ) | (344,000 | ) | (2,598,000 | ) | (2,187,000 | ) | ||||||||
| Interest and other income | 21,000 | 63,000 | 122,000 | 172,000 | ||||||||||||
| Loss before income taxes | (743,000 | ) | (281,000 | ) | (2,476,000 | ) | (2,015,000 | ) | ||||||||
| Income tax expense (benefit) | 163,000 | 48,000 | 390,000 | (296,000 | ) | |||||||||||
| Net loss | (906,000 | ) | (329,000 | ) | (2,866,000 | ) | (1,719,000 | ) | ||||||||
| Less: Net loss attributable to non-controlling interests | 286,000 | 312,000 | 1,120,000 | 797,000 | ||||||||||||
| Net loss attributable to American Shared Hospital Services | $ | (620,000 | ) | $ | (17,000 | ) | $ | (1,746,000 | ) | $ | (922,000 | ) | ||||
| Loss per common share: | ||||||||||||||||
| Basic | $ | (0.09 | ) | $ | (0.00 | ) | $ | (0.26 | ) | $ | (0.14 | ) | ||||
| Diluted | $ | (0.09 | ) | $ | (0.00 | ) | $ | (0.26 | ) | $ | (0.14 | ) | ||||
| Weighted Average Shares Outstanding: | ||||||||||||||||
| Basic | 6,773,000 | 6,632,000 | 6,748,000 | 6,593,000 | ||||||||||||
| Diluted | 6,773,000 | 6,632,000 | 6,748,000 | 6,593,000 | ||||||||||||
| American Shared Hospital Services | ||||||
| Balance Sheet Data | ||||||
| Balance Sheet Data | ||||||
| (Unaudited) | ||||||
| 9/30/2026 | 12/31/2025 | |||||
| Cash, cash equivalents and restricted cash | $ | 9,485,000 | $ | 3,712,000 | ||
| Current assets | $ | 19,059,000 | $ | 17,720,000 | ||
| Total assets | $ | 52,865,000 | $ | 55,479,000 | ||
| Current liabilities | $ | 23,627,000 | $ | 23,444,000 | ||
| Shareholders' equity American Shared Hospital Services | $ | 22,608,000 | $ | 24,034,000 | ||
| Outstanding shares | 6,650,000 | 6,575,000 | ||||
| American Shared Hospital Services | ||||||||||||||
| Adjusted EBITDA | ||||||||||||||
| Reconciliation of GAAP to Non-GAAP Adjusted Results | ||||||||||||||
| (Unaudited) | ||||||||||||||
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||
| Net loss attributable to American Shared Hospital Services | $ | (620,000 | ) | $ | (17,000 | ) | $ | (1,746,000 | ) | $ | (922,000 | ) | ||
| Less (plus): | Income tax expense (benefit) | 163,000 | 48,000 | 390,000 | (296,000 | ) | ||||||||
| Interest expense | 480,000 | 392,000 | 1,083,000 | 1,253,000 | ||||||||||
| Interest income | (40,000 | ) | (34,000 | ) | (122,000 | ) | (157,000 | ) | ||||||
| Depreciation and amortization expense | 1,342,000 | 1,454,000 | 3,982,000 | 4,411,000 | ||||||||||
| Stock-based compensation expense | 38,000 | 101,000 | 241,000 | 304,000 | ||||||||||
| Adjusted EBITDA | $ | 1,363,000 | $ | 1,944,000 | $ | 3,828,000 | $ | 4,593,000 | ||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.